PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLCSeptember 28, 2018Immuno-oncologyLung Cancer
CAR T-cell studies dominate ongoing cellular therapy trialsSeptember 26, 2018Immuno-oncologyLymphoma & Plasma Cell Disorders
Dramatic response from pembrolizumab in patient with Lynch syndromeSeptember 24, 2018Immuno-oncologyGynecologic CancerGastroenterologyGastrointestinal Cancer
PD-1/PD-L1 treatment linked to hyperprogressive disease in lung cancer patientsSeptember 20, 2018Immuno-oncologyLung Cancer
Fatal toxicities from checkpoint inhibitors vary by agentSeptember 19, 2018Immuno-oncologyMelanomaLung Cancer
Kymriah cost effectiveness depends on long-term outcomesSeptember 17, 2018Practice ManagementImmunotherapyImmuno-oncology
Skin signs may be good omens during cancer therapySeptember 13, 2018Nonmelanoma Skin CancerImmuno-oncologyPatient & Survivor CareMelanoma
HIV-associated Kaposi sarcoma responds to checkpoint inhibitorsSeptember 7, 2018Immuno-oncologySarcoma & GIST
PD1 mRNA may predict response to anti-PD1 monotherapy across cancer typesSeptember 4, 2018Immuno-oncologyMelanomaLung CancerRenal Cell Carcinoma
CAR T coverage: Drugmakers say no to patient reported outcomesAugust 30, 2018Practice ManagementImmuno-oncology
Nivolumab plus ipilimumab effective in melanoma brain metastasesAugust 27, 2018MelanomaCNS/Brain CancerImmuno-oncology
Adding checkpoint inhibitors to radiotherapy requires particular caution in this one scenarioAugust 24, 2018Immuno-oncologyLung CancerCNS/Brain CancerMelanoma
Baseline steroids may reduce efficacy of checkpoint inhibitorsAugust 24, 2018Lung CancerImmuno-oncology
Nivolumab plus ipilimumab boosts response rate in refractory esophagogastric cancerAugust 22, 2018Immuno-oncologyGastroenterologyGastrointestinal Cancer
